Vol 48, No 2 (2017)
Prace poglądowe / Reviews
Published online: 2017-04-01

open access

Page views 206
Article views/downloads 1020
Get Citation

Connect on Social Media

Connect on Social Media

Recommendations of Polish Myeloma Group concerning diagnosis and therapy of multiple myeloma and other plasmacytic dyscrasias for 2017

Anna Dmoszyńska1, Lidia Usnarska-Zubkiewicz2, Jan Walewski3, Ewa Lech-Marańda45, Adam Walter-Croneck6, Barbara Pieńkowska-Grela7, Grzegorz Charliński8, Wiesław Wiktor Jędrzejczak9, Bogdan Małkowski10, Krzysztof Jamroziak5, Agnieszka Druzd-Sitek3, Dominik Dytfeld11, Mieczysław Komarnicki11, Tadeusz Robak12, Artur Jurczyszyn13, Joanna Mańko6, Aleksander Skotnicki13, Sebastian Giebel14, Elżbieta Wiater15, Ryszard Czepko16, Janusz Meder3, Krzysztof Giannopoulos1718
DOI: 10.1016/j.achaem.2017.05.003
Acta Haematol Pol 2017;48(2):55-103.

Abstract

New drugs introduced in recent years to the therapy of multiple myeloma patients resulted in better responses and prolongation of overall survival. While therapeutic regimens based on bortezomib and thalidomide are recommended to most patients in first line therapy, lenalidomide represents the cornerstone for treatment of relapsed/refractory myeloma patients. Most patients profit from prolonged treatment composed of consolidation and maintenance treatment till progression. Besides the concept of longer treatment, it is recommended to start therapy in some patients earlier, taking into consideration biomarkers of active disease. In this article, we described therapeutic recommendation also for Waldenström macroglobulinemia and other plasmacytic dyscrasias.

Article available in PDF format

View PDF (Polish) Download PDF file